319 related articles for article (PubMed ID: 21718816)
1. The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking.
Leung P; Pickarski M; Zhuo Y; Masarachia PJ; Duong LT
Bone; 2011 Oct; 49(4):623-35. PubMed ID: 21718816
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of bone resorption by the cathepsin K inhibitor odanacatib is fully reversible.
Zhuo Y; Gauthier JY; Black WC; Percival MD; Duong LT
Bone; 2014 Oct; 67():269-80. PubMed ID: 25038310
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological inhibition of cathepsin K: A promising novel approach for postmenopausal osteoporosis therapy.
Mukherjee K; Chattopadhyay N
Biochem Pharmacol; 2016 Oct; 117():10-9. PubMed ID: 27106079
[TBL] [Abstract][Full Text] [Related]
4. A Mild Inhibition of Cathepsin K Paradoxically Stimulates the Resorptive Activity of Osteoclasts in Culture.
Pirapaharan DC; Søe K; Panwar P; Madsen JS; Bergmann ML; Overgaard M; Brömme D; Delaisse JM
Calcif Tissue Int; 2019 Jan; 104(1):92-101. PubMed ID: 30194476
[TBL] [Abstract][Full Text] [Related]
5. An Ectosteric Inhibitor of Cathepsin K Inhibits Bone Resorption in Ovariectomized Mice.
Panwar P; Xue L; Søe K; Srivastava K; Law S; Delaisse JM; Brömme D
J Bone Miner Res; 2017 Dec; 32(12):2415-2430. PubMed ID: 28745432
[TBL] [Abstract][Full Text] [Related]
6. Clinical and translational pharmacology of the cathepsin K inhibitor odanacatib studied for osteoporosis.
Stone JA; McCrea JB; Witter R; Zajic S; Stoch SA
Br J Clin Pharmacol; 2019 Jun; 85(6):1072-1083. PubMed ID: 30663085
[TBL] [Abstract][Full Text] [Related]
7. Polarized osteoclasts put marks of tartrate-resistant acid phosphatase on dentin slices--a simple method for identifying polarized osteoclasts.
Nakayama T; Mizoguchi T; Uehara S; Yamashita T; Kawahara I; Kobayashi Y; Moriyama Y; Kurihara S; Sahara N; Ozawa H; Udagawa N; Takahashi N
Bone; 2011 Dec; 49(6):1331-9. PubMed ID: 21983021
[TBL] [Abstract][Full Text] [Related]
8. A novel approach to inhibit bone resorption: exosite inhibitors against cathepsin K.
Panwar P; Søe K; Guido RV; Bueno RV; Delaisse JM; Brömme D
Br J Pharmacol; 2016 Jan; 173(2):396-410. PubMed ID: 26562357
[TBL] [Abstract][Full Text] [Related]
9. The resorptive apparatus of osteoclasts supports lysosomotropism and increases potency of basic versus non-basic inhibitors of cathepsin K.
Fuller K; Lindstrom E; Edlund M; Henderson I; Grabowska U; Szewczyk KA; Moss R; Samuelsson B; Chambers TJ
Bone; 2010 May; 46(5):1400-7. PubMed ID: 20097319
[TBL] [Abstract][Full Text] [Related]
10. Effects of pharmacological inhibition of cathepsin K on fracture repair in mice.
Soung do Y; Gentile MA; Duong LT; Drissi H
Bone; 2013 Jul; 55(1):248-55. PubMed ID: 23486186
[TBL] [Abstract][Full Text] [Related]
11. Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts.
Fuller K; Lawrence KM; Ross JL; Grabowska UB; Shiroo M; Samuelsson B; Chambers TJ
Bone; 2008 Jan; 42(1):200-11. PubMed ID: 17962093
[TBL] [Abstract][Full Text] [Related]
12. Cathepsin K Inhibition: A New Mechanism for the Treatment of Osteoporosis.
Duong le T; Leung AT; Langdahl B
Calcif Tissue Int; 2016 Apr; 98(4):381-97. PubMed ID: 26335104
[TBL] [Abstract][Full Text] [Related]
13. Cathepsin K-sensitive poly(ethylene glycol) hydrogels for degradation in response to bone resorption.
Hsu CW; Olabisi RM; Olmsted-Davis EA; Davis AR; West JL
J Biomed Mater Res A; 2011 Jul; 98(1):53-62. PubMed ID: 21523904
[TBL] [Abstract][Full Text] [Related]
14. Azanitrile Cathepsin K Inhibitors: Effects on Cell Toxicity, Osteoblast-Induced Mineralization and Osteoclast-Mediated Bone Resorption.
Ren ZY; Machuca-Gayet I; Domenget C; Buchet R; Wu Y; Jurdic P; Mebarek S
PLoS One; 2015; 10(7):e0132513. PubMed ID: 26168340
[TBL] [Abstract][Full Text] [Related]
15. Intracellular machinery for matrix degradation in bone-resorbing osteoclasts.
Vääräniemi J; Halleen JM; Kaarlonen K; Ylipahkala H; Alatalo SL; Andersson G; Kaija H; Vihko P; Väänänen HK
J Bone Miner Res; 2004 Sep; 19(9):1432-40. PubMed ID: 15312243
[TBL] [Abstract][Full Text] [Related]
16. Altered hematopoietic stem cell and osteoclast precursor frequency in cathepsin K null mice.
Jacome-Galarza C; Soung do Y; Adapala NS; Pickarski M; Sanjay A; Duong LT; Lorenzo JA; Drissi H
J Cell Biochem; 2014 Aug; 115(8):1449-57. PubMed ID: 24590570
[TBL] [Abstract][Full Text] [Related]
17. Osteoclasts from mice deficient in tartrate-resistant acid phosphatase have altered ruffled borders and disturbed intracellular vesicular transport.
Hollberg K; Hultenby K; Hayman A; Cox T; Andersson G
Exp Cell Res; 2002 Oct; 279(2):227-38. PubMed ID: 12243748
[TBL] [Abstract][Full Text] [Related]
18. Alendronate disturbs vesicular trafficking in osteoclasts.
Alakangas A; Selander K; Mulari M; Halleen J; Lehenkari P; Mönkkönen J; Salo J; Väänänen K
Calcif Tissue Int; 2002 Jan; 70(1):40-7. PubMed ID: 11907706
[TBL] [Abstract][Full Text] [Related]
19. Cathepsin K Deficiency Suppresses Disuse-Induced Bone Loss.
Moriya S; Izu Y; Arayal S; Kawasaki M; Hata K; Pawaputanon Na Mahasarakhahm C; Izumi Y; Saftig P; Kaneko K; Noda M; Ezura Y
J Cell Physiol; 2016 May; 231(5):1163-70. PubMed ID: 26460818
[TBL] [Abstract][Full Text] [Related]
20. Effects of odanacatib on bone-turnover markers in osteoporotic postmenopausal women: a post hoc analysis of the LOFT study.
Duong LT; Clark S; Pickarski M; Giezek H; Cohn D; Massaad R; Stoch SA
Osteoporos Int; 2022 Oct; 33(10):2165-2175. PubMed ID: 35711006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
